Polyclonal antibody production against bovine serum albumin conjugated artemisinin in rabbit

Kaboutari, J.1, Arab, H.A.1*, Foroumadi, A.2, Nikbakht, G.R.3, Taheri, M.4

1Department of Basic Sciences, Faculty of Veterinary Medicine, University of Share Kord, Share-Kord-Iran.
2Department of Pharmacology, Faculty of Veterinary Medicine, University of Tehran, Tehran-Iran.
3Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Tehran University of Medical Science, Tehran-Iran.
4Department of Pathobiology, Faculty of Veterinary Medicine, University of Tehran, Tehran-Iran.
5Central Research Laboratory, Faculty of Veterinary Medicine, University of Tehran, Tehran-Iran.

(Received 18 March 2008, Accepted 23 June 2008)

Abstract: The aim of the present study was to produce a polyclonal antibody against bovine serum albumin (BSA) conjugated with artemisinin. To gain an immunogenic character of artemisinin, a carboxyl group was added to it using mixed anhydride method. Then, the reactive compound of artemisinin was conjugated with BSA. The BSA+artemisinin were injected to white female New Zealand rabbits for two times. In the first injection, the Fraid's complete adjuvant was used, and two weeks later, a booster injection was carried out with a Fraid's incomplete adjuvant. Two weeks later, blood samples were collected; their serum were separated and frozen until assessment. The production of antibody against BSA+artemisinin was assayed by Immunoblot technique. Antibody was separated and concentrated by saturated ammonium sulfate. The assay confirmed the successful production of an antibody against BSA+artemisinin as a fundamental step in investigation of pharmacodynamics and pharmacokinetics of artemisinin.

Key words: Artemisia sieberi, artemisinin, polyclonal antibody, BSA-conjugation.

Introduction
Artemisinin and its several derivatives have impressive parasitidal activity against malaria agents including strains of Plasmodium resistant to conventional anti malarial compounds and cerebral malaria, with high efficiency and negligible toxicity (Li et al., 1994). Artemisinin was extracted, for the first time, from a Chinese medical plant Qinghao (Artemisia annua). The plant has been used as antipyretic and anti malarial agent in traditional Chinese medicine for more than 2000 years (Toufigh Gordi, 2001). It is a sesquiterpene trioxane lacton containing a peroxide bridge that is essential for its therapeutic activities (China Cooperative Research on Qinghaosu, 1982; Klayman et al., 1985; Woerdenbag et al., 1994).

Coccidiosis is an intestinal infection caused by the intracellular protozoan parasite of the genus Eimeria. It is a major parasitic disease of poultry with substantial economic burden, estimated to cost around 2 billion $ in annual losses world wide (Zhang and Zeng, 2005).

For many years, prophylactic use of different chemical drugs has been the primary mean of controlling this disease (Patricia and Fetter, 2002), but the increasing problem of Eimeria resistance against many drugs has prompted a majority of research efforts to seek an alternative methods of coccidiosis control (Williams, 2002). As apart of such efforts Artemisia plant has been a candidate
being a potential source of anti coccidial activities in chickens.

Patricia and co-workers (1997) for the first time showed the protective effect of the dried leaves of Artemisia annua and pure artesiminin against coccidiosis experimentally induced by different species of Eimeria. It was shown that the dried leaves of A. annua were able to protect the birds against Eimeria tenella (Patricia et al., 1997). Arab et al determined and quantitated the amount of artemisinin in another species of Artemisia-Artemisia sieberi- and showed that the plant extract was able to reduce the coccidian infection in broilers (Arab et al., 2006).

Despite the numerous studies on the pharmacodynamics of artemisinin in malaria, there is no evidence to show the mechanism(s) of the action of this compound in avian coccidiosis. It seems that the first step to understand the mechanism of action of artemisinin is to determine the site of action of drug and tracing it in the body tissues. A simple and reliable method to fulfill this assignment is to trace the administrated drug by Immunohistochemistry method using polyclonal antibodies.

Since, artemisinin is too small to be immunogenic (mol. wt 282), it must be conjugated to a large carrier protein to take action as the primary immunogenic agent. Furthermore, it lacks a reactive group to bond to a carrier protein. To overcome this, Ferreira and Janick (1996) derivatized artemisinin to dihydroartemisinin carboxymethylether in three steps without disturbing the peroxide bridge, and then linked this reactive compound to either Thyroglobulin (TGB) or BSA. The conjugates were mixed and emulsified with complete or incomplete Freund's adjuvant, and then they were injected to female New Zealand rabbits for six to seven times. The ELISA showed that the polyclonal antibodies induced against artesiminin-TGB conjugate in rabbits but not against artesiminin-BSA (Ferreira and Janick, 1996). The aim of this study was to produce a polyclonal antibody against BSA conjugated artemisinin using Ferreira and Janick modified method. This antibody can be used as a research probe to trace the artemisinin in the intestinal tissue by Immunohistochemical technique.

**Materials and Methods**

**Artemisinin derivatization:** To insert a reactive compound on the artemisinin structure, it was derivatized to a reactive compound in three phases (Ferreira and Janick, 1996).

**Phase 1. Reduction of artemisinin:** Five hundred mg (1.77 mmol) artemisinin (Alexi's biochemicals, France) was dissolved in 40 ml of methanol (Merck, Germany) at room temperature. The solution was cooled to 0-5°C and then 300 mg (17.9 mmol) of NaBH₄ was added over a period of 30 minutes. A TLC system (2% methanol in CHCl₃) was used to monitor the reaction until artemisinin was completely...
reduced during 2-3 hours. The reaction was stopped by decreasing the pH to 5-6 using 2.6 ml of 30% acetic acid in methanol. Methanol was evaporated by a vacuum system and then the reduced artemisinin (dihydroartemisinin) was washed out three times by 50 ml of ethyl acetate (Sigma -Aldrich, USA). Each wash was separately filtered through a Whatman filter paper no.1 (Schiecher-Schuell, Germany), mixed with others and reflushed under vacuum. The clear ethyl acetate solution was evaporated to yield 84% of dihydroartemisinin. (Fig. 1)

Phase 2. Addition of an ester moiety to dihydroartemisinin: The reaction was initiated by dissolving 420 mg (148 mmol) of dihydroartemisinin in 25 ml of anhydrous diethyl ether (Merck, Germany), dried with Na-benzophenone, and then 3 gr of dry molecular sieve (3A°, Sigma, USA) and 7.4 mmol of ethyl glycolate (700μl, Aldrich,USA) were added to the mixture. The temperature of the solution was reduced to 0ºC, and then 3 drops of 50% solution of boron trifluoride etherate (Merck, Germany) in anhydrous diethyl ether were added to it. The mixture was stirred for 5 hours under nitrogen and monitored by TLC (20% ethyl acetate in petroleum ether). An additional 15 ml of anhydrous diethyl ether, 700 μl of ethyl glycolate and 1 drop of boron trifluoride etherate were added to the mixture. The mixture was stirred for additional 3 hours until no signs of dihydroartemisinin could be detected on TLC (20% ethyl acetate in petroleum ether). The molecular sieves were filtered and washed out with anhydrous diethyl ether, and then the solvent was evaporated to yield a yellowish oily compound. This oily compound was extracted 3 times with petroleum ether (Merck, Germany) and then the petroleum ether was evaporated to obtain a colorless oily compound. (Fig.2)

Phase 3. Hydrolysis of the ester to yield the carboxy group: One equivalent NaOH (2.86 mmol or 114 mg) was dissolved in 50 ml of 95% ethanol, and then it was added to dihydroartemisinin carboxymethylester compound obtained at phase 2. The mixture was stirred at room temperature over night to produce the sodium salt of the ester. Ethanol was evaporated under vacuum and the remaining solid was washed out with ethyl acetate. To remove the remaining starting materials, the sodium salt of the ester was dissolved in water and the clear solution was acidified using 1N HCl. The resulting product which was a white solid, was extracted with ethyl acetate, and then washed with water and dried with Na2SO4. The solvent was evaporated to obtain 230 mg of a crude epimeric mixture (α , β) of the desired carboxylic acid (dihydroartemisinin carboxymethylether) (Fig.3). This compound was purified by column chromatography using Silica gel (Merck, Germany 230-400 mesh) with a mobile phase of 40% ethyl acetate, 59% hexane (Merck, Germany), and 1% acetic acid. Phosphomolibdic
Conjugation of dihydroartemisinin carboxymethyl ether to BSA: When TLC confirmed the derivatization process, the conjugation of dihydroartemisinin carboxymethyl ether to BSA was started using mixed anhydride method (Ferreira and Janick, 1996). 40 mg (0.117 mmol) of dihydroartemisinin carboxymethyl ether was dissolved in 2 ml of anhydrous dioxane and kept on ice. 100 mg (0.0015 mmol) BSA fraction V (Sigma-Aldrich, USA) was dissolved in 5 ml of doubled distilled water while pH was adjusted to 9.5, cooled to 10°C, and then 2 ml of anhydrous dioxane was added to the solution. 50 μl of tri-n-butyl amine (Merck, Germany) was added to dihydroartemisinin carboxymethylether solution and stirred under nitrogen for 30 minutes at 10°C. Thirty μl isobutyl chloroformate (Merck, Germany) was added to this solution and then it was continually stirred under nitrogen for 20 minutes at 10°C. After adding of another 2 ml anhydrous dioxane to this mixture, it was added drop wise to the BSA solution in H2O/dioxane (5:2) whilst it was stirred in an ice-cold temperature. When two solutions were mixed, the pH of the mixture decreased to 6.9, and then it was adjusted to 7.4 by addition of 1 ml NaHCO3. The solution was stirred overnight in a cold room and then it was centrifuged at 13000g for 5 minutes. The supernatant was dialyzed in water in a cold room for 3 days (2 changes of 1 liter water per day).

Animal immunization: Three white adult female New Zealand rabbits were prepared from Pasteur institute (Iran Pasteuv Institute, Tehran, Iran) and kept on a standard diet and environmental conditions. A blood sample was taken from each animal as negative control and then two intramuscular injections carried out to induce immunization. The first injection was consisted of 500 μg BSA+artemisinin conjugate (1:1 ratio) in PBS, and then it was mixed and emulsified with complete Freund's adjuvant to a final volume of 1ml for each rabbit. Two weeks later, a booster injection was done with 500 μg BSA+ artemisinin conjugate mixed with incomplete Freund's adjuvant (1:1) to a final volume of 1ml. After 14 days, 20-30 ml blood sample was collected from each rabbit via jugular vein, and then they were centrifuged to separate the sera.

Antibody production assessment: A standard Immunoblots method (Ausubel et al., 2002) was used to assay production of antibody against BSA-artemisinin conjugate. Aliquots of 5 μl artemisinin, 5 μl BSA-artemisinin conjugate and 5 μl of BSA were spotted on PVDF membranes (0.45-mm pore size, Roche, Laboratories, Germany) and positively charged Nylon membrane (Roche, laboratory, Germany). Membranes were blocked with 5% skim milk in physiologic buffer solution (PBS, 0.02 M Tris base-0.385 M NaCl-0.1%) and washed with Tris-buffered saline containing 0.05% Tween 20 (TPBS).
The membranes were incubated separately with specific polyclonal antibody provided against artemisinin, and then preimmune and immune serum samples diluted in TPBS-BSA (PBS 0.02%, Tween 20 and 3% BSA) at 37°C for 2h and it was washed again. The labeled protein G recombinant-proxidase (1:500) (Sigma, Germany) was used in place of secondary antibody for primary sera. The membranes were incubated with protein G for 1h at 37°C, and washed out three times with TPBS. The reaction was developed with 0.3mg α-chloronaphtol (Sigma, Germany) in 100ml of PBS containing 30μl of 30% H2O2, and then the sheet paper membranes were placed in running tap water for 5min to stop the reaction.

When Immunoblot confirmed the production of antibody, saturated ammonium sulfate was added for antibody separation and concentration (Hudson and hay, 1989). Finally the concentrated antibody was labeled using Fluorescein Isothiocyanate (FITC) (Gosling, 2000). IHC examination by using Avidin-Biotine Complex technique and produced polyclonal anti artemisinin antibody was done on intestinal samples of chickens infected with experimental coccidiosis and received artemisinin orally. (Data not shown).

Results
Artemisinin derivatization and conjugation
At the first phase of derivazation, dihydroartemisinin was obtained by evaporation of clear ethyl acetate solution. The second phase of derivazation resulted in the attachment of an ester moiety to dihydroartemisinin. After the extraction of the oily compound with petroleum ether, a colorless oily compound containing a mixture of α.β epimers of dihydroartemisinin carboxymethylester was obtained. In the third phase of artemisinin derivatization, a carboxy group was added on the dihydroxyartemisinin through hydrolysis of the ester. The dilydoryartemisinin carboxy methyl ether was purified by column chromatography and its structure was confirmed by TLC spot. The TLC analysis was used for monitoring of the progress of the reactions during all phases.

Antibody production and IHC: The inoculation of conjugated dihydroartemisinin carboxymethylether +BSA to rabbit successfully induces antibody production against artemisinin. During Immunoblots, it was found that the Nylon membrane was better than PVDF membrane, since PVDF could not absorb artemisinin. Therefore, here we have shown only the result obtained from the experiments using Nylon membrane. The results of the Immunoblots assessments have been shown in Figure 4 (preimmune spots) and 5 (immune serum). The antibody production assay showed while the blue spots were not appeared on the membrane one, there were two spots on the membrane two; one in the place of artemisinin alone and the second was on the place of BSA-artemisinin conjugate. As Figure 4
and 5 shows there were no spot on place of BSA, indicating that there was no antibody against this compound in preimmune and immune serum. However, Figure 5 illustrates that there are two clear blue spots where artemisinin alone and artemisinin+BSA conjugate were fixed and reacted with immune serum indicating the presence of anti artemisinin and anti BSA+artemisinin conjugate in the immune serum.

Figures 6 and 7 show the IHC of the cecal tissue of chicken received artemisinin and Figure 8 shows the ICH of Duodenal tissue in which brown colored area of the epithelial tissue is positively stained with artemisinin.

Discussion

In the present study, we successfully produced a polyclonal antibody against BSA+artemisinin conjugate that is useful for Immunohistochemistry work. Because of the hapten nature of the artemisinin, at first a reactive carboxy group was added on it, and then it was conjugated with a suitable carrier, BSA, using mixed anhydride method. TLC studies confirmed the artemisinin derivatization while an endoperoxide group remained intact. The compound obtained at the end of the derivatization had a reactive carboxy group appropriate for conjugation to BSA and induction of immunization in rabbit. After injection of conjugated compound, the Immunoblot assay showed the success of immunization, leading to production of antibody against artemisinin. The production of antibody against artemisinin showed that the BSA successfully linked to dihydroartemisinin carboxymethylether compound by its carboxyl group using the mixed anhydride method.

Development of drug resistance against conventional anti coccidian drugs has paid the increasing attention toward the development of new groups of drugs including artemisinin. The effects of artemisinin on avian coccidiosis especially against E. tenella have been shown by few studies (Patricia et al., 1997; Arab et al., 2006). However, there is no evidence to show the mechanism(s) by which artemisinin exerts its anti coccidian effect. One of the simplest ways to understand the mechanism of anti coccidian effects of artemisinin is to produce antibody against it and then trace the site of action of the compound by Immunohistochemistry technique.

Ferreira and Janick (1996) in an attempt to produce polyclonal antibodies against artemisinin extracted from Artemisia annua linked the dihydroartemisinin carboxymethylether to either TGB or BSA. The artemisinin+TGB and -BSA conjugates were injected to rabbits, but only artemisinin+TGB was able to induce the antibody production which was attributed to failure in suitable conjugation of artemisinin to BSA. Ferreira et al used an ELISA method to confirm the production and specificity of the antibodies. (Ferreira and Janick, 1996). While they failed to make an active conjugation of BSA+artemisinin to induce antibodies, we could successfully conjugate artemisinin with BSA using a modified immunization. In our work the raise of artemisinin polyclonal antibody was confirmed by Immunoblot method.

Artemisinin is a hapten and by itself can not be used to induce antibody. Hapten is a non antigenic compound, usually with low molecular weight that can not stimulate the immune system. But if it be conjugated with an antigenic compound (carrier), an antigenic character can be created in the conjugation. Hapten-carrier complex or new antigen is able to induce antibody production so that the specificity of antibody is preserved for hapten (Lansteiner, 1962). If an animal is immunized against hapten+carrier complex, in addition to the anti hapten antibody and anti carrier antibody, there are specific antibodies which are directed against epitopes resulted from hapten-carrier conjugation. Thus, when a complex of hapten-carrier is injected to animals, different antibodies will be produced against hapten, carrier and carrier-hapten complex (Lansteiner, 1962). In the present study, the immunoblots test showed that antibodies were raised against both artemisinin (hapten) and artemisinin+BSA (hapten carrier complex). BSA can not stimulate rabbit immune system and thus will not produce antibody against itself. Because, it is a heterologus antigen and there...
are many epitopic similarities between BSA and rabbit serum albumin (Landsteiner, 1962). There is
evidence that BSA cleared of its larger phagocytable
particles, is less immunogenic than the regular one. In
addition, BSA is sometimes able to induce tolerance
at dose 1mg in the rabbit, whereas at 0.1 mg induced
slightly less tolerance but the difference was not
significant (Frei et al., 1968). The concentration of
BSA used in our study was in the range to induce
tolerance and thus no antibody was induced against it.

Artemisinin and its derivatives are found to be
changed into an active metabolite, dihydroartemisinin, during their metabolisms in the
body (Navartnam et al., 2000). Therefore, antibody
produced against artemisinin+BSA conjugate would
be useful if it can react with this metabolite. Ferreira
and Janick (1996) have shown cross reactivity of anti
artemisinin antibody against artemisitene,
dihydroartemisinin, arteannuin B, and artmisinic
acid using polyclonal antibodies induced by injection
of artemisinin+TGB conjugation in the rabbit
(Ferreira and Janick, 1996). In addition suitable
results obtained from IHC examination using
produced anti artemisinin antibody practically
confirmed the usefulness of the antibody and its cross
reactivity with artemisinin metabolite(s). Thus, it
seems that the polyclonal antibody induced against
artemisinin can be used to detect artemisinin and
different derivatives including dihydroartemisinin in
the body tissues.

In conclusion, we could successfully raise a polyclonal antibody against BSA conjugated artemisinin
in rabbits. This production can be a fundamental tool
to investigate pharmacodynamics and pharmacokinetics of artemisinin and its derivatives
in different animals by immunohistochemical
technique.

Acknowledgement

This work was supported by the Iranian National
Science Foundation (INSF) and University of
Tehran, Iran.

References

1. Arab, H.A., Rahbari, S., Rassouli, A., Moselmi.,
M.H., Khosravairad, F. (2006) Determination of
artemisinin in Artemisia sieberi and antococcidial
effect of the plant extract in broiler chickens. Trop.
3. China Cooperative Research Group on Qinghaosu
and its derivatives as Anti malaria’s, (1982). Trad.
(1968) Immunogenic tolerance induced in the adult
rabbit with Modified BSA. J. Immunol. 101: 605-
610.
analysis of artemisinin from Artemisia annua using
polyclonal antibodies. Phytochemistry. 41: 97-104.
3rdEd. Blackwell scientific publishing company,
antimalarial drug from china. Science. 28:1049-
1056.
(1994) Clinical trials of artemisinin and its
derivatives in the treatment of malaria in china.
11. Navartnam, V., Mansor, S. M., Sit, N.W., Grace, J.,
Lio, Q., Olliaro, P. (2000) Pharmacokinetics of
39: 255-270.
components of Artemisia annua on coccidian
biology and immunobiology of Eimeria species and
in diagnosis and control of infection with these
coccidial parasites of poultry. Clin. Microb. Rev.15:


تولید آنتی‌بادی پیلی کلوناال علیه آتره میزین احیا شده به آلومین سرم گاو در خرگوش

چگونه


code: 1607